Biora Therapeutics Inc. (BIOR) NASDAQ

$0.22 -0.02 (-8.39%)

Market Cap: $48.03M

As of 12/06/22 04:00 PM EST. Market closed.

(BIOR)

Biora Therapeutics Inc. (BIOR) NASDAQ

$0.22 -0.02 (-8.39%)

Market Cap: $48.03M

As of 12/06/22 04:00 PM EST. Market closed.

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life ... read more

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. read less

COMPANY PROFILE
Sector
Health Care and Social Assistance
Industry
Medical Laboratories
CEO
Harry Stylli
Full Time Employees
642
URL
Address
4330 La Jolla Village Dr Ste 200, California, San Diego, 92122.
Sector
Health Care and Social Assistance
Industry
Medical Laboratories
CEO
Harry Stylli
Full Time Employees
642
Address
4330 La Jolla Village Dr Ste 200, California, San Diego, 92122.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$0
Previous Close
$0.23
Days Range
$0.22 - $0.24
52 week range
$0.21 - $2.86
Volume
14,002
Avg. Volume (30 days)
1,550,038
Market Cap
$48.03M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
223,170,617
Open
$0
Previous Close
$0.23
Days Range
$0.22 - $0.24
52 week range
$0.21 - $2.86
Volume
14,002
Avg. Volume (30 days)
1,550,038
Market Cap
$48.03M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
223,170,617

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR BIORA THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
NEUMANN CLARKE See Remarks Nov 15, 2022 Option Exercise $0.27 4,529 1,223 542,398 Nov 16, 2022, 09:49 PM
MOHANTY ADITYA P. Chief Executive Officer Nov 15, 2022 Option Exercise $0.27 175,071 47,269 2,799,858 Nov 16, 2022, 09:48 PM
dEsparbes Eric Chief Financial Officer Nov 15, 2022 Option Exercise $0.27 5,194 1,402 710,122 Nov 16, 2022, 09:48 PM
NEUMANN CLARKE See Remarks Aug 15, 2022 Option Exercise $1.04 1,355 1,409 546,927 Aug 16, 2022, 06:02 PM
dEsparbes Eric Chief Financial Officer Aug 15, 2022 Option Exercise $1.04 5,952 6,190 708,429 Aug 16, 2022, 05:58 PM
Sarna Surbhi Director Jul 05, 2022 Sale $0.61 7,517 4,585 148,774 Jul 05, 2022, 06:48 PM
NEUMANN CLARKE See Remarks May 15, 2022 Option Exercise $0.75 8,305 6,229 308,320 May 17, 2022, 05:27 PM
dEsparbes Eric Chief Financial Officer May 15, 2022 Option Exercise $0.75 10,387 7,790 412,784 May 17, 2022, 05:18 PM
dEsparbes Eric Chief Financial Officer Feb 15, 2022 Option Exercise $1.90 4,919 9,346 191,478 Feb 17, 2022, 04:05 PM
Hashemi Hutan Chief Compliance Officer Feb 15, 2022 Option Exercise $1.90 187 355 28,495 Feb 17, 2022, 04:05 PM
NEUMANN CLARKE See Remarks Feb 15, 2022 Option Exercise $1.90 1,716 3,260 131,782 Feb 17, 2022, 04:05 PM
NEUMANN CLARKE See Remarks Nov 15, 2021 Option Exercise $3.47 752 2,609 133,498 Nov 17, 2021, 04:05 PM
Hashemi Hutan Chief Compliance Officer Nov 15, 2021 Option Exercise $3.47 645 2,238 28,682 Nov 17, 2021, 04:05 PM
Cooper Matthew T General Manager, Diagnostics Nov 15, 2021 Option Exercise $3.47 700 2,429 134,039 Nov 17, 2021, 04:05 PM
Silvestry Damon See Remarks Nov 15, 2021 Option Exercise $3.47 4,566 15,844 291,499 Nov 17, 2021, 04:05 PM
NEUMANN CLARKE See Remarks Aug 15, 2021 Option Exercise $1.66 2,336 3,878 134,250 Aug 17, 2021, 04:03 PM
Silvestry Damon See Remarks Aug 15, 2021 Option Exercise $1.66 1,478 2,453 289,178 Aug 17, 2021, 04:03 PM
Stylli Harry Chairman & CEO Aug 15, 2021 Option Exercise $1.66 10,335 17,156 14,816,522 Aug 17, 2021, 04:03 PM
Hashemi Hutan Chief Compliance Officer Aug 15, 2021 Option Exercise $1.66 158 262 22,440 Aug 17, 2021, 04:01 PM
dEsparbes Eric Chief Financial Officer Aug 15, 2021 Option Exercise $1.66 5,718 9,492 196,397 Aug 17, 2021, 04:00 PM
Cooper Matthew T Chief Scientific Officer Aug 15, 2021 Option Exercise $1.66 560 930 127,852 Aug 17, 2021, 04:00 PM
Seelye Troy Chief Information Officer Aug 06, 2021 Option Exercise $1.94 23,673 45,926 59,756 Aug 09, 2021, 09:19 PM
Athyrium Opportunities Fund (A) LP 10% Owner Jun 01, 2021 Buy $2.86 1,268,115 3,626,809 28,299,741 Jun 03, 2021, 04:46 PM
Seelye Troy Chief Information Officer May 15, 2021 Option Exercise $2.36 1,925 4,543 83,429 May 17, 2021, 08:46 PM
Hashemi Hutan Chief Compliance Officer May 15, 2021 Option Exercise $2.36 69 163 22,598 May 17, 2021, 08:44 PM
Silvestry Damon Chief Operating Officer Apr 15, 2021 Option Exercise $3.41 3,681 12,552 290,656 Apr 19, 2021, 09:38 PM
dEsparbes Eric Chief Financial Officer Apr 15, 2021 Option Exercise $3.41 13,690 46,683 202,115 Apr 19, 2021, 09:32 PM
Shihabi Sami Chief Commercial Officer Mar 04, 2021 Option Exercise $4.05 2,623 10,623 35,062 Mar 08, 2021, 05:20 PM
NEUMANN CLARKE General Counsel and Secretary Mar 04, 2021 Option Exercise $4.05 1,564 6,334 50,735 Mar 08, 2021, 05:17 PM
Gianakopoulos George Senior Vice President of Sales Mar 04, 2021 Option Exercise $4.05 490 1,985 21,789 Mar 08, 2021, 05:17 PM
Cooper Matthew T Chief Scientific Officer Mar 04, 2021 Option Exercise $4.05 1,609 6,516 49,352 Mar 08, 2021, 05:16 PM
dEsparbes Eric Chief Financial Officer Mar 04, 2021 Option Exercise $4.05 1,608 6,512 92,423 Mar 08, 2021, 05:14 PM
Stylli Harry Chairman & CEO Feb 15, 2021 Option Exercise $5.60 11,287 63,207 14,596,972 Feb 17, 2021, 05:23 PM
Shihabi Sami Chief Commercial Officer Feb 15, 2021 Option Exercise $5.60 932 5,219 37,685 Feb 17, 2021, 05:15 PM
NEUMANN CLARKE General Counsel and Secretary Feb 15, 2021 Option Exercise $5.60 663 3,713 52,299 Feb 17, 2021, 05:11 PM
Gianakopoulos George Senior Vice President of Sales Feb 15, 2021 Option Exercise $5.60 377 2,111 22,279 Feb 17, 2021, 05:09 PM
dEsparbes Eric Chief Financial Officer Feb 15, 2021 Option Exercise $5.60 5,361 30,022 94,031 Feb 17, 2021, 05:04 PM
Cooper Matthew T Chief Scientific Officer Feb 15, 2021 Option Exercise $5.60 662 3,707 50,961 Feb 17, 2021, 05:00 PM
Gianakopoulos George Senior Vice President of Sales Dec 19, 2020 Option Exercise $6.32 843 5,328 22,656 Dec 22, 2020, 07:26 PM
Stylli Harry Chairman & CEO Dec 19, 2020 Option Exercise $6.32 8,615 54,447 14,608,259 Dec 22, 2020, 07:23 PM
NEUMANN CLARKE General Counsel and Secretary Dec 19, 2020 Option Exercise $6.32 1,726 10,908 52,962 Dec 22, 2020, 07:22 PM
Shihabi Sami Chief Commercial Officer Dec 19, 2020 Option Exercise $6.32 1,757 11,104 38,617 Dec 22, 2020, 07:21 PM
dEsparbes Eric Chief Financial Officer Dec 19, 2020 Option Exercise $6.32 1,228 7,761 99,392 Dec 22, 2020, 07:19 PM
Cooper Matthew T Chief Scientific Officer Dec 19, 2020 Option Exercise $6.32 1,805 11,408 51,623 Dec 22, 2020, 07:18 PM
Silvestry Damon Chief Operating Officer Dec 16, 2020 Buy $4.58 58,081 265,857 221,230 Dec 17, 2020, 04:30 PM
Silvestry Damon Chief Operating Officer Dec 15, 2020 Buy $4.07 63,870 259,951 163,149 Dec 16, 2020, 04:26 PM
Alter Jeffrey D. Director Dec 14, 2020 Buy $4.85 20,000 97,000 38,335 Dec 15, 2020, 07:27 PM
Athyrium Capital Management, LP 10% Owner Dec 07, 2020 Buy $3.27 4,128,440 13,499,999 26,991,626 Dec 09, 2020, 05:35 PM
Athyrium Opportunities Fund (A) LP 10% Owner Dec 07, 2020 Buy $3.27 4,128,440 13,499,999 26,991,626 Dec 09, 2020, 05:35 PM
Stylli Harry Chairman & CEO Dec 02, 2020 Buy $3.27 152,905 499,999 14,616,874 Dec 04, 2020, 04:30 PM
Cooper Matthew T Chief Scientific Officer Sep 02, 2020 Buy $8.55 99 846 44,277 Sep 04, 2020, 03:50 PM
Cooper Matthew T Chief Scientific Officer Sep 03, 2020 Buy $8.55 9,151 78,241 53,428 Sep 04, 2020, 03:50 PM
Stylli Harry Chairman & CEO Aug 19, 2020 Buy $8.94 10,000 89,400 14,463,969 Aug 21, 2020, 04:15 PM
Athyrium Capital Management, LP 10% Owner Jun 23, 2020 Buy $15.00 3,333,333 49,999,995 23,303,346 Jun 25, 2020, 04:25 PM
Athyrium Opportunities Fund (A) LP 10% Owner Jun 23, 2020 Buy $15.00 3,333,333 49,999,995 23,303,346 Jun 25, 2020, 04:18 PM
Stylli Harry Chairman & CEO Jun 19, 2020 Buy $15.00 33,333 499,995 1,038,635 Jun 23, 2020, 07:54 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
NEUMANN CLARKE See Remarks 11/15/2022 1,223
MOHANTY ADITYA P. Chief Executive Officer 11/15/2022 47,269
dEsparbes Eric Chief Financial Officer 11/15/2022 1,402
NEUMANN CLARKE See Remarks 08/15/2022 1,409
dEsparbes Eric Chief Financial Officer 08/15/2022 6,190
Sarna Surbhi Director 07/05/2022 4,585
NEUMANN CLARKE See Remarks 05/15/2022 6,229
dEsparbes Eric Chief Financial Officer 05/15/2022 7,790
dEsparbes Eric Chief Financial Officer 02/15/2022 9,346
Hashemi Hutan Chief Compliance Officer 02/15/2022 355
NEUMANN CLARKE See Remarks 02/15/2022 3,260
NEUMANN CLARKE See Remarks 11/15/2021 2,609
Hashemi Hutan Chief Compliance Officer 11/15/2021 2,238
Cooper Matthew T General Manager, Diagnostics 11/15/2021 2,429
Silvestry Damon See Remarks 11/15/2021 15,844
NEUMANN CLARKE See Remarks 08/15/2021 3,878
Silvestry Damon See Remarks 08/15/2021 2,453
Stylli Harry Chairman & CEO 08/15/2021 17,156
Hashemi Hutan Chief Compliance Officer 08/15/2021 262
dEsparbes Eric Chief Financial Officer 08/15/2021 9,492
Cooper Matthew T Chief Scientific Officer 08/15/2021 930
Seelye Troy Chief Information Officer 08/06/2021 45,926
Athyrium Opportunities Fund (A) LP 10% Owner 06/01/2021 3,626,809
Seelye Troy Chief Information Officer 05/15/2021 4,543
Hashemi Hutan Chief Compliance Officer 05/15/2021 163
Silvestry Damon Chief Operating Officer 04/15/2021 12,552
dEsparbes Eric Chief Financial Officer 04/15/2021 46,683
Shihabi Sami Chief Commercial Officer 03/04/2021 10,623
NEUMANN CLARKE General Counsel and Secretary 03/04/2021 6,334
Gianakopoulos George Senior Vice President of Sales 03/04/2021 1,985
Cooper Matthew T Chief Scientific Officer 03/04/2021 6,516
dEsparbes Eric Chief Financial Officer 03/04/2021 6,512
Stylli Harry Chairman & CEO 02/15/2021 63,207
Shihabi Sami Chief Commercial Officer 02/15/2021 5,219
NEUMANN CLARKE General Counsel and Secretary 02/15/2021 3,713
Gianakopoulos George Senior Vice President of Sales 02/15/2021 2,111
dEsparbes Eric Chief Financial Officer 02/15/2021 30,022
Cooper Matthew T Chief Scientific Officer 02/15/2021 3,707
Gianakopoulos George Senior Vice President of Sales 12/19/2020 5,328
Stylli Harry Chairman & CEO 12/19/2020 54,447
NEUMANN CLARKE General Counsel and Secretary 12/19/2020 10,908
Shihabi Sami Chief Commercial Officer 12/19/2020 11,104
dEsparbes Eric Chief Financial Officer 12/19/2020 7,761
Cooper Matthew T Chief Scientific Officer 12/19/2020 11,408
Silvestry Damon Chief Operating Officer 12/16/2020 265,857
Silvestry Damon Chief Operating Officer 12/15/2020 259,951
Alter Jeffrey D. Director 12/14/2020 97,000
Athyrium Capital Management, LP 10% Owner 12/07/2020 13,499,999
Athyrium Opportunities Fund (A) LP 10% Owner 12/07/2020 13,499,999
Stylli Harry Chairman & CEO 12/02/2020 499,999
Cooper Matthew T Chief Scientific Officer 09/02/2020 846
Cooper Matthew T Chief Scientific Officer 09/03/2020 78,241
Stylli Harry Chairman & CEO 08/19/2020 89,400
Athyrium Capital Management, LP 10% Owner 06/23/2020 49,999,995
Athyrium Opportunities Fund (A) LP 10% Owner 06/23/2020 49,999,995
Stylli Harry Chairman & CEO 06/19/2020 499,995
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2022
03/31/2022
0.90%
2Q

Period of Report: 09/30/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2022
0.90%
2Q